…

The clinical stakes of the new assay become clearer when placed against the epidemiological backdrop described in the source material. Clostridioides difficile infection remains one of the most common healthcare-associated infections worldwide, with recent global surveillance analyses placing incidence at roughly 66 cases per 100,000 population in North America and about 36 per 100,000 in Europe. The burden falls disproportionately on hospitalized patients, elderly individuals over 65, and those with underlying health conditions, and notably 56% of cases occur in patients who received antibiotics within the previous 12 weeks. Mortality estimates range from 14,000 to 30,000 CDI-related deaths annually, figures that underscore why even incremental improvements in diagnostic turnaround could translate into meaningful clinical impact.

Current treatment guidelines in the United States and Europe recommend empiric therapy with fidaxomicin or vancomycin as preferred first-line agents for both initial and severe cases, with metronidazole reserved only for low-risk, non-severe infections. This empiric approach exists largely because antimicrobial susceptibility testing is rarely performed in routine practice. The technical obstacles are considerable: C. difficile grows fastidiously, the reference agar dilution method recommended by CLSI is labor-intensive and requires up to 48 hours, and no standardized clinical breakpoints have been established for agents such as fidaxomicin. Broth microdilution, while amenable to high-throughput workflows, lacks formal standardization and has shown variable performance, including MIC underestimation and limited reproducibility. Fidaxomicin is also absent from commercial susceptibility panels, and disk diffusion, despite showing good correlation with MIC-based methods in epidemiological investigations, remains formally discouraged by CLSI pending standardized breakpoints.

The urgency of reinstating susceptibility testing into the C. difficile diagnostics arsenal is reinforced by emerging resistance data. Recent reports documented 5.6% fidaxomicin-resistant isolates in 2025, with minimum inhibitory concentrations reaching up to 32 µg/mL. Most of these resistant isolates were recovered following fidaxomicin therapy, a pattern that highlights the risk of resistance emerging under treatment pressure and raises concerns about the long-term sustainability of purely empiric approaches. Treatment failure and rising antimicrobial resistance have been flagged in multiple recent analyses, suggesting that the window in which empiric therapy can be relied upon without laboratory confirmation may be narrowing.

Against this background, the Marseille team’s two-phase assay design reflects a pragmatic response to the specific demands of anaerobic susceptibility testing. Phase I focused on optimizing liquid culture conditions, inoculum, and growth kinetics to guarantee reproducible bacterial suspensions, an essential prerequisite given the scarcity of standardized recommendations for cultivating C. difficile in liquid medium for susceptibility purposes. Phase II then exposed these standardized suspensions to antibiotics and used early tabletop scanning electron microscopy imaging to evaluate bacterial ultrastructure faster than conventional methods, with quantitative SEM analysis enabling MIC range estimations that were validated against the agar dilution gold standard.

The eight isolates examined in the proof-of-concept study were drawn from the Collection de Souches de l’Unité des Rickettsies and spanned both toxigenic and non-toxigenic profiles, with toxin gene detection for tcdA and tcdB quantified by qPCR. Species identification was confirmed using MALDI-TOF mass spectrometry, and baseline MICs were determined by agar dilution following CLSI M11-A8 guidelines. All eight isolates proved susceptible to fidaxomicin, with MIC values ranging from 0.125 to 0.25 mg/L, and susceptible to vancomycin, with MIC values of 1 to 2 mg/L. The non-toxigenic isolates showed fidaxomicin MICs of 0.125 to 0.25 mg/L and vancomycin MICs of 1 to 2 mg/L, while the toxigenic isolates, which carried both toxin genes at low cycle threshold values indicating high toxin gene loads, showed fidaxomicin MICs of 0.25 mg/L and vancomycin MICs of 2 mg/L. This homogeneity of susceptibility within the panel means the study validated the assay’s accuracy against known susceptible phenotypes rather than demonstrating its ability to discriminate resistant strains, an important caveat when interpreting the concordance between SEM-based and agar dilution MICs.

The choice of fidaxomicin and vancomycin as test antibiotics aligns with their status as the preferred first-line therapies in current guidelines, making them the most clinically relevant targets for any accelerated susceptibility assay. Fidaxomicin in particular has lacked commercial susceptibility panels, so demonstrating that SEM imaging can detect its effects on C. difficile within hours addresses a specific gap in the available testing arsenal. Vancomycin, while more established, still benefits from rapid MIC confirmation in severe cases where treatment response variability has been documented.

The application of tabletop SEM to anaerobic bacteria represents an extension of methodology previously demonstrated for aerobic organisms. Earlier studies by the same research group showed that tabletop SEM enables rapid discrimination between resistant and susceptible bacterial strains following just two hours of antibiotic exposure, substantially reducing turnaround time compared with conventional methods. Translating that approach to strict anaerobes required overcoming additional technical hurdles, including maintaining anaerobic conditions throughout the exposure period and optimizing broth conditions that support reproducible C. difficile growth. The reported reduction in turnaround time from 48 hours to approximately 7 hours without compromising accuracy suggests that the optimized culture conditions combined with early SEM imaging can capture antibiotic effects, including growth inhibition, reduced bacterial viability, and pronounced morphological alteration, as early as three hours following exposure.

The morphological dimension of the SEM readout deserves particular attention. Unlike conventional MIC methods that rely solely on visible growth inhibition, SEM imaging captures ultrastructural changes in antibiotic-exposed bacteria, providing an additional layer of information that may prove valuable in ambiguous cases or when distinguishing bactericidal from bacteriostatic effects. The ability to quantify these effects from image analysis also opens the possibility of semi-automated interpretation, though the study’s proof-of-concept scope means such workflows remain to be developed and validated.

Several limitations inherent to the study design temper the immediate clinical applicability of the findings. The isolate panel was small, comprising eight strains with uniformly susceptible phenotypes, so the assay’s performance against resistant isolates, particularly those with elevated fidaxomicin MICs such as the 32 µg/mL strains documented in recent surveillance, remains untested. The absence of clinical breakpoints for fidaxomicin means that even rapid MIC results would currently inform epidemiological surveillance and specialized consultation rather than routine therapeutic decision-making. Standardization of the broth microdilution framework for C. difficile, which has shown variable performance in prior evaluations, would need formal validation before the SEM-based assay could be considered for clinical implementation. Nevertheless, the demonstration that SEM-based MIC estimation is feasible for strict anaerobes establishes a methodological foundation that could support future multi-center evaluations, expansion to resistant phenotype panels, and eventual integration into CDI diagnostics workflows where accelerated susceptibility information could guide therapy selection in severe or recurrent cases.

The broader significance of the work lies in its positioning of phenotypic susceptibility testing as a realistic component of anaerobic diagnostics. By achieving reliable MIC concordance with the agar dilution reference method within a single working day, the SEM-AST assay addresses the principal barrier that has kept C. difficile susceptibility testing confined to specialized reference laboratories. If subsequent validation confirms the assay’s accuracy across diverse resistance phenotypes and establishes standardized interpretation criteria, the approach could help reinstate laboratory-guided therapy for CDI at a moment when rising fidaxomicin resistance and treatment failure are making empiric approaches increasingly difficult to sustain.

Subject of Research: Novel assay for accelerated anaerobic phenotypic susceptibility testing for Clostridioides difficile

Article Title: Novel assay for accelerated anaerobic phenotypic susceptibility testing for Clostridioides difficile

Article References: Boukili, M., Zmerli, O., Bellali, S., Daoud, S., Abou Abdallah, R., Fenollar, F., & Bou Khalil, J. (2026). Novel assay for accelerated anaerobic phenotypic susceptibility testing for Clostridioides difficile. Frontiers in Bacteriology, 5, Article 1952528. https://doi.org/10.3389/fbrio.2026.1952528

Image Credits: AI Generated

DOI: 10.3389/fbrio.2026.1952528

Keywords: Novel, assay, accelerated, anaerobic, phenotypic, susceptibility, testing, Clostridioides, difficile, scientific research